Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepQuant SHUNT in severe alcoholic hepatitis
NCT03087968Phase 1Withdrawn
- Sponsor
- HepQuant
- Start
- Jul 2016
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alcoholic hepatitis (AH) comparing GS-4997 + Prednisolone with Prednisolone + Placebo (2 arms). Primary endpoint: Disease Severity Index at 24 weeks. Planned start Jul 2016; status: withdrawn.
02
Drugs
selonsertib
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT03087968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087968.